There are some studies reporting the preclinical efficacy of CAR T cells in HER2+ GBM, ovarian breast, osteosarcoma, and medulloblastoma of orthotopic xenogeneic models (47–51). This evidence concerns the gene ERBB2 and medulloblastoma.